SpliceBio Announces First Patient Dosed in Phase 1/ 2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SpliceBio United Kingdom United States of America

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt diseaseView original content:https://www.prnewswire.co.uk/news-releases/splicebio-announces-first-patient-dosed-in-phase-12-astra-study-of-sb-007-a-dual-aav-gene-therapy-for-stargardt-disease-302400970.html